Wearable Autoinjector for Wound Infection Treatment

The proposed program addresses the need to replace the combat wound medication packet (CWMP) with a wearable device capable of delivering treatment for the prevention of infection in a prolonged care setting. The ability to treat penetrating wounds with antibiotics before surgery will be a major hurdle in maintaining combat power. In response to this need, Triton Systems, Inc. has leveraged its existing efforts in wearable devices and microfluidic platforms to develop a novel wearable autoinjector for continuous drug delivery in prolonged care scenarios. In the Phase I program, Triton designed and developed proof-of-concept prototypes demonstrating the capability to meet treatment delivery requirements. In the proposed Phase II program, Triton will further refine the Phase I proof-of-concept prototype, maturing it into a viable product. This will include an optimization of our wearable autoinjector for demonstration of deep treatment penetration and prevention of infection.